The European Society of Cardiology (ESC) congress is the largest cardiovascular congress in the world. This year’s event also included the World Congress of Cardiology and attracted over 30,000 delegates, who gathered at the Paris Expo Porte de Versailles to participate in a programme of over 500 different sessions across the full spectrum of cardiovascular medicine.
The European Society of Cardiology (ESC) congress is the largest cardiovascular congress in the world. This year’s event also included the World Congress of Cardiology and attracted over 30,000 delegates, who gathered at the Paris Expo Porte de Versailles to participate in a programme of over 500 different sessions across the full spectrum of cardiovascular medicine.
The European Society of Cardiology (ESC) has just announced the release of its latest guidelines on the management of acute pulmonary embolism (PE), which have been updated for the first time since 2014.
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is primarily regarded as a disease that affects adults. Although the incidence in adults is approximately 100 times higher than in children, it has been increasingly recognized that paediatric VTE is also associated with substantial morbidity and mortality.
Venous thromboembolism (VTE) is a leading cause of mortality and morbidity in patients with cancer. The risk of VTE is ~4–7-times higher in patients with cancer compared with those without, and the risk varies by cancer type.
2019 marked a special year for the International Society on Thrombosis and Haemostasis (ISTH), being the 50th anniversary of its founding and the first year of the new annual congress format in collaboration with the ISTH Scientific and Standardization Committee (SSC).
Co-morbidities occur frequently in patients with atrial fibrillation (AF) and can further increase the risk of stroke and/or bleeding in this already at-risk population. In one retrospective, observational study of patients with AF in the US (N=1297), 98% had at least one additional co-morbidity and 20.5% had a Charlson Comorbidity Index score of ≥3, indicating that they had a high risk of mortality due to serious concomitant disease.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting upwards of 30 million people globally, and is a major cause of stroke. One third of all patients with AF also have chronic kidney disease (CKD), a condition characterised by impaired renal function.
The vast majority of patients with type 2 diabetes will die of a cardiovascular (CV) event such as stroke; therefore, it is crucial that physicians look for opportunities to reduce the risks of these events.
Venous thromboembolism (VTE) is a common cardiovascular disorder associated with substantial morbidity and mortality. Anticoagulation is highly effective in reducing the risk of recurrent VTE; however, treatment may be more complicated in frail patients.
Patients who develop a venous thromboembolism (VTE; deep vein thrombosis [DVT] or pulmonary embolism [PE]) require fast, effective anticoagulation therapy to treat the acute event and prevent VTE recurrence.
More than 200 neurologists, cardiologists and various other specialists braved the wintery Berlin weather to attend European Society of Cardiology (ESC) Heart and Stroke, the annual conference of the ESC Council for Stroke. Since its inception at ESC 2016, the Council for Stroke has grown to more than 1200 members, and this was reflected in the increased participation at this event compared with the first meeting in 2018.
Atrial fibrillation (AF) is a major risk factor for stroke; however, up to 40% of patients with AF are asymptomatic. The first evidence of asymptomatic AF can be devastating, because stroke is the first symptom in ~25% of patients. This highlights the need for strategies to facilitate earlier diagnosis to allow the initiation of anticoagulation therapy to help reduce the risk of AF-related stroke.